Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michelle H. Gurel"'
Publikováno v:
BMC Pharmacology and Toxicology, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Background Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs dai
Externí odkaz:
https://doaj.org/article/bd4ebd8f97e340638966c36be2f56f7e
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 18, Iss 1, Pp 1-9 (2017)
BMC Pharmacology and Toxicology, Vol 18, Iss 1, Pp 1-9 (2017)
Background Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs daily medica
Publikováno v:
Patient preference and adherence
Michelle H Gurel,1 Paul R Bruening,2 Christine Rhodes,2 Kathleen G Lomax31Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, MA, USA; 2Nicholas Research Associates International, New York, NY, USA; 3Medical Affairs, Ipsen Biophar
Autor:
Laurence Katznelson, Murray B. Gordon, Kevin C.J. Yuen, Sharon A. Rhoads, Olivia S. Chu, David M. Cook, Kellie L. Spiller, Michelle H. Gurel, Valentina Corazzini, Beverly M. K. Biller, Roberto Salvatori
Publikováno v:
Pituitary. 16(2)
Weight-based (WB: 0.03 mg/kg) and fixed dose (FD: 1–1.5 mg) regimens of the glucagon stimulation test (GST) have been used to evaluate GH and cortisol secretion in children and adults, respectively. However, experience of the WB regimen in assessin